@article{article_1682396, title={USTEKINUMAB EFFECTIVENESS AND SUSTAINABILITY IN ULCERATIVE COLITIS AND CROHN’S DISEASE}, journal={Journal of Istanbul Faculty of Medicine}, volume={88}, pages={256–263}, year={2025}, DOI={10.26650/IUITFD.1682396}, author={İstemihan, Zülal and Teberik Kama, Ebru and Altın, Soner and İmanov, Ziya and Şenkal, İbrahim Volkan and Nuriyev, Kanan and Rüstemzade, Aynure and Genç Uluçeçen, Sezen and Yağlı, Mehmet Akif and Dağcı, Gizem and et al.}, keywords={Crohn hastalığı, ülseratif kolit, ustekinumab}, abstract={Objective: This study aimed to investigate the effectiveness, sustainability, and side effects of ustekinumab in patients with ulcerative colitis (UC) and Crohn’s disease (CD). Material and Methods: The data of 48 inflammatory bowel disease patients who were unresponsive to previous treatment and were followed up at a tertiary centre were retrospectively investigated. Demographic features, characteristics of bowel diseases, treatment experiences, laboratory and endoscopic features, and disease scores [Crohn’s Disease Activity Index (CDAI) and Simple Clinical Colitis Activity Index (SCCAI)] were analysed. Results: Of the total 48 patients, 35 (73%) were CD and 26 (54.2%) were women. The mean age of the patients was 42.1±13.3 years, and the mean age of disease was 136.8±92 months. There was previous use of biological agents in 100% of both UC and CD. The most common reason for switching to ustekinumab in patients was a lack of response to previous biologics (90%). The mean duration of use of ustekinumab was 17.1±8 months. At the end of the followup, 71% of the CD patients had CDAI<150 and were in complete clinical remission, and 53.8% of the UC patients had SCCAI<5 and were in complete clinical remission. Control endoscopy was performed for 13 UCs, and 6 (46.2%) had endoscopic remission. Control endoscopy was performed for 5 CDs, and 3 (60%) had endoscopic remission. Conclusion: Ustekinumab is an effective treatment method in achieving clinical remission in CD and UC resistant to previous treatments in the followup.}, number={4}, publisher={İstanbul Üniversitesi}